Hidden costs of PANS: new study reveals financial toll of IVIG treatment

NCT ID NCT06818656

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study surveyed 65 U.S. families to understand the economic and quality-of-life impact of IVIG treatment for PANS/PANDAS. Researchers asked about medical visits, insurance, work absences, and children's school attendance. The goal is to shed light on the hidden costs of treating—or not treating—this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IVIG (intravenous immunoglobulin)

What this could lead to

If successful, this research could highlight the economic and social burden of PANS/PANDAS and support better insurance coverage or treatment access.

What could go wrong

This is a small, completed survey study—not a treatment trial. It measures costs and quality of life, not whether IVIG works. Results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANDAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neuroinflammatory Diseases PANDAS pediatric acute-onset neuropsychiatric syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brain Inflammation Collaborative

    Delafield, Wisconsin, 53018, United States